T cell engineered with a novel nanobody‐based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

T cell engineered with a novel nanobody‐based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy

Published:2019-02-06 Issue:9 Volume:71 Page:1259-1267
ISSN:1521-6543
Container-title:IUBMB Life
language:en
Short-container-title:IUBMB Life

Author:

Hajari Taheri Fatemeh¹^ORCID,Hassani Mahmoud¹²,Sharifzadeh Zahra¹,Behdani Mehdi³,Arashkia Arash⁴,Abolhassani Mohsen¹

Affiliation:

1. Department of ImmunologyHybridoma Lab, Pasteur Institute of Iran Tehran Iran

2. Department of Molecular MedicineTehran University of Medical Sciences Tehran Iran

3. Department of Molecular MedicinePasteur Institute of Iran Tehran Iran

4. Department of a Molecular VirologyPasteur Institute of Iran Tehran Iran

Funder

Pasteur Institute of Iran

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Genetics,Molecular Biology,Biochemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/iub.2019

Reference69 articles.

1. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

2. Targeting the tumor vasculature to enhance T cell activity

3. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia

4. Tumor vessel-injuring ability improves antitumor effect of cytotoxic T lymphocytes in adoptive immunotherapy

5. The Basic Principles of Chimeric Antigen Receptor Design

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent updates on allogeneic CAR-T cells in hematological malignancies;Cancer Cell International;2024-09-03

2. Progress in the Utilization of Nanobody CAR-T Cell in Cancer Immunotherapy;Journal of Biomedical Nanotechnology;2024-08-01

3. CAR-T cell technologies that interact with the tumour microenvironment in solid tumours;Expert Review of Clinical Immunology;2024-07-17

4. Nanobody-based CAR NK cells for possible immunotherapy of MICA+ tumors;PNAS Nexus;2024-04-30

5. Advances in tumor vascular growth inhibition;Clinical and Translational Oncology;2024-03-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3